We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Multi-Organoid System Provides Novel Platform for T2DM Research

Multi-Organoid System Provides Novel Platform for T2DM Research

Multi-Organoid System Provides Novel Platform for T2DM Research

Multi-Organoid System Provides Novel Platform for T2DM Research

Credit: Pixabay
Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Multi-Organoid System Provides Novel Platform for T2DM Research"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Type 2 diabetes (T2DM) is a systematic multi-organ metabolic disease, which is characterized by dynamic interplay among different organs.

Pancreatic islet-liver axis is closely associated with normal glucose regulation and homeostasis maintenance. The dysfunction of the interplay between these organs may lead to T2DM progression.

Recently, a group led by Prof. QIN Jianhua from the Dalian Institute of Chemical Physics (DICP) of the Chinese Academy of Sciences (CAS) developed a multi-organoid system from human induced pluripotent stem cells (hiPSCs) to simulate human liver-islet axis in normal and T2DM. 

"Stem cell-derived organoid, a new class of 3D tissues, has the key structural and functional features of in vivo counterparts," said Prof. QIN.

This newly developed multi-organoid system could simulate human liver-pancreatic islet axis in physiological and pathological conditions, and enable 3D co-culture of hiPSC-derived liver and islet organoids for up to 30 days.

The researchers found that the generated liver and islet organoids exhibited favorable growth and improved tissue-specific functions in this perfused microfluidic 3D culture system.

"The sensitive glucose-stimulated insulin secretion was from the islet organoids and it increased glucose utilization in the liver organoids," said Prof. QIN. This reflected the cooperative interaction between the two organs in this perfused co-culture system.

Transcriptional analyses revealed that the activated signaling pathways were associated with glucose/CYP450 metabolism and glycolysis/gluconeogenesis in liver and islet organoids.

What's more, this microfluidic islet-liver organoid system exhibited mitochondrial dysfunction and decreased glucose transport capacity under hyperglycemic conditions, which might be attributed to the alleviation by treatment with an anti-diabetic drug.

"This novel system can not only reflect the feedback loop within the liver-islet axis, but also exhibit relevant responses to high glucose and anti-diabetes drug, which is not easily achieved by conventional cell culture and animal models," said Prof. QIN. "It will provide a unique platform for the study of complex T2DM pathogenesis and drug development."

Reference: Tao T, Deng P, Wang Y, et al. Microengineered multi‐organoid system from hiPSCs to recapitulate human liver‐islet axis in normal and type 2 diabetes. Adv Sci. 2021:2103495. doi: 10.1002/advs.202103495

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.